Roots Analysis is a global market research, competitive intelligence & strategic consulting firm serving pharma, biotech, medical device and healthcare industry
Mohali
Joined May 2013
- Tweets10.7K
- Following482
- Followers792
- Likes230
Pinned Tweet
Personalized cancer vaccines are moving closer to the mainstream.
Recent Phase III melanoma data showed 82.2% recurrence-free survival at 24 months for a personalized mRNA-based investigational therapy + pembrolizumab, vs 70.0% for pembrolizumab alone.
At Roots Analysis, we believe the next big question is how to manufacture and scale personalized oncology therapies efficiently.
#Oncology #mRNA #CancerVaccines #PrecisionMedicine #Biotech #RootsAnalysis
The recurrence-free survival results are promising, but where personalized vaccines fit alongside evolving neoadjuvant immunotherapy strategies is another important question.
@dr_yakupergun @YGaritaonaindia what further evidence would most influence your view of their role in routine melanoma care?
The INTerpath-001 results raise an important question beyond clinical efficacy: how efficiently can patient-specific cancer vaccines move from manufacturing to routine clinical use?
@ProfGLongMIA @HTawbi_MDPhD - from your perspective, what will be the biggest challenge to broader adoption: patient selection, manufacturing turnaround, or treatment accessibility?
Roots Analysis retweeted
An important milestone for senescence-targeted immunotherapy. The real breakthrough will be demonstrating selective clearance of senescent cells with a strong safety profile. Will the initial clinical study assess senescence biomarkers alongside cancer treatment outcomes?
The next GLP-1 blockbuster may not be the one delivering the highest weight-loss percentage.
As competition intensifies, the real differentiator could be how effectively therapies translate clinical success into sustained patient adoption.
For pharma companies, this raises a strategic question:
Will the next market leader be determined by superior science or superior patient accessibility?
#GLP1 #Obesity #Biopharma #PharmaInnovation
🤖 Made with AI
🛰️ Earth is becoming the world's most powerful data engine.
From AI-powered geospatial analytics to real-time Earth observation, satellite intelligence is transforming how industries make decisions.
The global Satellite Data Services Market is projected to reach USD 100.45 billion by 2035, growing at a 20.28% CAGR.
The future of data isn't just in the cloud. It's in orbit.
🔗 rootsanalysis.com/satellite-…
#SatelliteData #SpaceTech #GeospatialAI #EarthObservation #RootsAnalysis
The future of dentistry is going digital. 🦷
From AI diagnostics to advanced restorative technologies, innovation is reshaping dental care.
📈 2026: $44.71B
🚀 2035: $133.68B
📊 CAGR: 12.94%
Explore: rootsanalysis.com/reports/de…
#DigitalDentistry #RootsAnalysis
🤖 Made with AI
Pills vs injections isn't the real GLP-1 battle.
The bigger question: will oral drugs take market share or bring entirely new patients into treatment?
Roots Analysis forecasts a $180B GLP-1 market by 2035.
@novonordiskus @EliLillyandCo what wins: efficacy, convenience or access?
#GLP1 #Pharma
Insights from research report by Roots Analysis on Extractables and Leachables Testing Market by Type of Container / Device Tested (Container / Closures and Packaging Materials, Single Use Systems and Processing Equipment, Medical Devices and Others), Type of Technique Used (Chromatography, Spectroscopy, and Other Techniques), Company Size, Application (Parenteral Drug Products, Inhalation Drug Products, and Oral Solutions and Suspensions) and Geographical Regions – Trends and Forecast 2026-2035
some of the emerging companies in this space include: @Intertek, @Merck_lifesci, @WuXi_AppTec, @EurofinGenomics, @BostonAnalytic, @JordiLabs, @GatewayAnalytic, @ImpactAnalytic, @SelvitaCRO, @RecipharmAB, @Accuprec, @AurigaResearch
The future of drug safety is becoming more human.
Precision Toxicology Market:
2026: $13.8B
2040: $51.8B
CAGR: 9.9%
AI, organ-on-chip and human-relevant models are reshaping toxicity testing.
Explore: rootsanalysis.com/reports/pr…
#DrugDiscovery #Toxicology
🤖 Made with AI
AI chips are getting faster. But what about the connections between them?
Retimers are becoming critical to high-speed AI infrastructure.
📈 Market: $1.83B (2026) → $4.71B (2035)
11.1% CAGR
Explore: rootsanalysis.com/retimer-ma…
#Semiconductors #AI #RootsAnalysis
🤰🔬 What if software could help transform prenatal screening into smarter, more informed decisions?
Prenatal Diagnostic Software is reshaping how healthcare professionals analyze data, support clinical decisions, and navigate pregnancy care. 🧬📊
As technology advances, what’s next for this evolving market?
📈 Explore the insights from Roots Analysis’ Prenatal Diagnostics Report.
#PrenatalDiagnostics #HealthTech #MedTech #DigitalHealth #MarketIntelligence
Could radiopharmaceuticals reshape precision oncology?
The global market is projected to grow from $13.1B in 2026 to $38.6B by 2040, at an 8.0% CAGR.
The opportunity goes beyond therapeutics—into theranostics, partnerships & isotope supply.
#Radiopharmaceuticals #Oncology
🤖 Made with AI
When reading an industry report, what do you check first?
0%Market size & growth
0%Latest industry trends
0%Leading companies
0%Future opportunities
0 votes • Final resultsThe next energy revolution could be hydrogen.
The global green hydrogen market is projected to grow from $1.5B (2024) to $125.3B (2035) at a 49.5% CAGR.
What's driving the shift? Clean energy, industrial decarbonization and sustainable fuels.
🔗 rootsanalysis.com/green-hydr…
#GreenHydrogen #CleanEnergy
🤖 Made with AI
What if your next ride arrived from the sky?
Flying cars are moving beyond science fiction, and the market opportunity is taking shape.
According to Roots Analysis, the Urban Air Mobility Market could reach $206.79B by 2040, growing at a 27.85% CAGR.
Would you trust a flying taxi for your daily commute?
#RootsAnalysis #FlyingCars #FutureOfMobility
AI Drug Discovery Has a $1.46 Billion Question
AstraZeneca’s insitro deal and Iambic’s IPO reveal the next test for AI: deciding which drug programs deserve the cost of human trials.
